Metsera Inc
MTSR51.900USD
+0.200+0.39%
收盘 10/03, 16:00（美东）报价延迟15分钟
5.44B总市值
亏损市盈率 TTM
关于 Metsera Inc 公司
Metsera, Inc. 是一家临床阶段的生物技术公司，致力于开发注射和口服营养刺激激素 (NuSH) 类似物肽，用于治疗肥胖、超重和相关疾病。该公司利用其专有的 MINT NuSH 类似物肽库以及其脂质优化半衰期增强 (HALO) 半衰期延长平台和其 MOMENTUM 口服 NuSH 类似物肽递送平台来提供高度差异化的产品候选物。其产品线包括 MET-097i、MET-233i / MET-233i + MET-097i 和 MET-224o。其先进产品候选物 MET-097i 是一种完全偏向的、每月一次的、皮下注射的超长效 GLP-1 RA。MET-233i 是一种皮下注射的超长效胰岛淀粉样肽类似物，具有增强的溶解性和与其他 NuSH 类似物肽的混溶性。 MET-224o 是一种口服、完全偏向的超长效 GLP-1 RA。该公司的产品线还包括 MET-002o、MET-AMYo、MET-034i、MET-067i 和 MET-PYYi。
Metsera Inc简介
公司代码MTSR
公司名称Metsera Inc
上市日期Jan 31, 2025
CEOMr. Christopher Whitten Bernard
员工数量74
证券类型Ordinary Share
年结日Jan 31
公司地址3 World Trade Center
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编10007
电话12127846595
网址https://metsera.com/
公司代码MTSR
上市日期Jan 31, 2025
CEOMr. Christopher Whitten Bernard
Metsera Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Paul L. Berns
Mr. Paul L. Berns
Independent Director
Independent Director
957.56K
--
Mr. Matthew Lang, J.D.
Mr. Matthew Lang, J.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Dr. Brian Hubbard, Ph.D.
Dr. Brian Hubbard, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Steven Marso, M.D.
Dr. Steven Marso, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
Independent Director
Independent Director
--
--
Dr. Clive A. Meanwell, M.D.
Dr. Clive A. Meanwell, M.D.
Executive Chairman of the Board, Founder
Executive Chairman of the Board, Founder
--
--
Mr. Christopher Whitten Bernard
Mr. Christopher Whitten Bernard
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher J. (Chris) Visioli
Mr. Christopher J. (Chris) Visioli
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
--
--
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Paul L. Berns
Mr. Paul L. Berns
Independent Director
Independent Director
957.56K
--
Mr. Matthew Lang, J.D.
Mr. Matthew Lang, J.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Dr. Brian Hubbard, Ph.D.
Dr. Brian Hubbard, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Steven Marso, M.D.
Dr. Steven Marso, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月25日 周一
更新时间: 8月25日 周一
持股股东
股东类型
持股股东
持股股东
占比
ARCH Venture Partners
25.47%
Fidelity Management & Research Company LLC
14.97%
Validae Health, L.P
12.13%
Alphabet, Inc.
4.71%
Newpath Partners LP
4.63%
其他
38.09%
持股股东
持股股东
占比
ARCH Venture Partners
25.47%
Fidelity Management & Research Company LLC
14.97%
Validae Health, L.P
12.13%
Alphabet, Inc.
4.71%
Newpath Partners LP
4.63%
其他
38.09%
股东类型
持股股东
占比
Venture Capital
36.88%
Investment Advisor
32.29%
Corporation
16.76%
Investment Advisor/Hedge Fund
12.27%
Hedge Fund
2.47%
Individual Investor
0.91%
Research Firm
0.17%
Bank and Trust
0.06%
Pension Fund
0.03%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
173
88.61M
84.17%
+4.23M
2025Q2
133
95.51M
90.92%
+74.51M
2025Q1
104
95.08M
90.50%
+81.16M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
ARCH Venture Partners
26.82M
25.47%
+2.22M
+9.04%
Feb 03, 2025
Fidelity Management & Research Company LLC
15.76M
14.97%
+590.52K
+3.89%
Jun 30, 2025
Validae Health, L.P
12.77M
12.13%
--
--
Mar 31, 2025
Alphabet, Inc.
4.96M
4.71%
--
--
Jun 30, 2025
Newpath Partners LP
4.88M
4.63%
+4.88M
--
Jan 31, 2025
SB Global Advisers Ltd
4.82M
4.58%
--
--
Jun 30, 2025
MIC Capital Management UK LLP
4.54M
4.31%
--
--
Jun 30, 2025
VR Adviser, LLC
3.75M
3.56%
--
--
Jun 30, 2025
Wellington Management Company, LLP
3.43M
3.26%
+1.03M
+42.69%
Jun 30, 2025
Janus Henderson Investors
3.39M
3.22%
+482.50K
+16.61%
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月2日 周四
更新时间: 10月2日 周四
机构名称
占比
Roundhill GLP-1 & Weight Loss ETF
4.21%
ALPS Medical Breakthroughs ETF
2.17%
Virtus LifeSci Biotech Clinical Trials ETF
0.79%
SPDR S&P Biotech ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
BNY Mellon US Small Cap Core Equity ETF
0.1%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
ProShares Hedge Replication ETF
0.02%
Global X Russell 2000 ETF
0.02%
查看更多
Roundhill GLP-1 & Weight Loss ETF
占比4.21%
ALPS Medical Breakthroughs ETF
占比2.17%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.79%
SPDR S&P Biotech ETF
占比0.16%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.1%
BNY Mellon US Small Cap Core Equity ETF
占比0.1%
JPMorgan BetaBuilders US Small Cap Equity ETF
占比0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0.03%
ProShares Hedge Replication ETF
占比0.02%
Global X Russell 2000 ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
